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Background: In Fiji, hepatitis B (HB) vaccine was introduced into childhood immunization program in 1989 and has
been administered as a pentavalent since 2006. This study aimed to: (i) survey and examine the extent to which HB
infection continue to occur in children, adolescents and adults in Fiji, and (ii) determine HB coverage rates and
timeliness of vaccine administration to children.
Methods: Serum samples of children, adolescents and adults (aged 6 months to <5 years, 16–20 years, and 21–49
years, respectively) collected between 2008–2009 were tested for serologic markers of HB virus infection namely,
HB surface antigen (HBsAg), anti-HBs and anti-HB core antigen (anti-HBc). Health record card of each child was
reviewed.
Results: None of the participating children (0/432) was positive for HBsAg. Overall prevalence of HBsAg among
adolescents and adults was 5.6% (7/124) and 3.2% (12/370), respectively. High prevalence (98.1%) of anti-HBs was
observed in children. An estimated 17.4% of adolescents and adults had evidence of past HBV infection (anti-HBc
positive), of which 87.2% recovered from infection but the remaining 12.8% developed chronic infection. Percentage of
children who completed at least 3 doses of HB immunization was 99.3%, and who received them on schedule
was 58.5%.
Conclusion: Although sample populations for this study is less robust compared to 1998, the prevalence of HBsAg
and anti-HBc in children and adults before and after the implementation of the immunization program is much lower.
The findings are a positive step in showing that Fiji’s HB vaccine control program is achieving its objectives.
Keywords: Hepatitis B immunization program, EPI, Immunization coverage, SeroprevalenceIntroduction
Hepatitis B virus (HBV) is a DNA virus and humans are
the only known natural host. HBV infection can lead to
a person’s premature death from cirrhosis, liver failure
and liver cancer. HBV is transmissible through several
routes: (i) percutaneous - injecting drug use, exposure to
contaminated blood or body fluid; (ii) sexual - hetero-
sexual or male homosexual activity; (iii) vertical - from
mother to infant; and (iv) horizontal - between children* Correspondence: moritak@nagasaki-u.ac.jp
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unless otherwise stated.and household contacts through skin lesions or sharing
of blood-contaminated toothbrushes and razors [1,2].
Children aged between one and five years when in-
fected with HBV have a 20-50% chance of developing
chronic infection [3]. This may progress to hepatocellu-
lar carcinoma later in the adult life at a rate of 5% per
decade, which is 100 to 300 times the rate observed
among uninfected people in the general population [4].
Because the risk of chronic infection is inversely corre-
lated with age, people who are infected as children bear
a large burden in terms of morbidity and mortality [2].
Immunization against HBV is the most effective meas-
ure to prevent HBV infection. In Fiji, hepatitis B (HB)tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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program in 1989 [5]. The vaccine administered since 2006
is a monovalent vaccine for the birthdose and a pentava-
lent (DTP-HepB-Hib) vaccine for the succeeding three
doses [6]. A segment of the population under the age of
20 years was 38.5% in 2007 in Fiji, and an estimated 40%
of the total population would have been covered by HB
immunization in 2009 [7].
A seroprevalence study conducted among pre-school
immunized children in Fiji in 1998 revealed that the
prevalence of hepatitis B surface antigen (HBsAg), anti-
body to hepatitis B surface antigen (anti-HBs) and anti-
body to hepatitis core antigen (anti-HBc) was 0.7%,
77.0%, and 5.3%, respectively [8]. Among unimmunized
mothers the prevalence was 6.6%, 57.9% and 67.2%, re-
spectively. The present study was initiated as part of a
technical cooperation titled “Project for strengthening
expanded immunization program in the Pacific region”
funded by the Japan International Cooperation Agency
(JICA), an official overseas aid agency under the
Japanese government. The project was characterized by
activities in line with the PIPS (Pacific Immunization
Programme Strengthening) strategy, which is the
regional framework that enables PIPS international
partners, including JICA, WHO, UNICEF, CDC and
other agencies to share the vision of cooperation and
support to immunization programs in the Pacific Island
Countries.
The information yield by this study defines the magni-
tude of trends of HB infection status among different age
groups and presents an impact of the HB immunization
program performance.Figure 1 Flow-chart of the study.Results
Hepatitis B serologic survey
A total of 950 participants were recruited from the three
health divisions of Fiji (Central, Western and Northern
Divisions, Figure 1) but only 926 recruits (432 out of
450 children, 124 out of 125 adolescents and 370 out of
375 adults, Table 1) were included in the serologic sur-
vey. Eighteen children were excluded from the survey
for any of the following reasons: small volume of blood
obtained, unsuccessful venipuncture and a very sick
child. An adolescent and five adults were later excluded
from the study because they did not show up at the des-
ignated clinic at the appointed time and date or because
their bad physical condition made them unfit for blood
sampling.
Four hundred thirty two children were negative for
HBsAg; while adolescents and adults had a 5.6% (7/
124) and 3.2% (12/370) prevalence, respectively and a
combined prevalence of 3.84% (19/494) (Table 2). The
prevalence of HBsAg was highest in adolescents (5.6%)
but it was not statistically significant (P = 0.4253, chi-
squared test) from that of the other two populations.
The prevalence [1.6% (2/124)] of HBsAg in adults,
aged 21 to 29 years, was considerably lower than that
[4.1% (10/246)] observed in adults older than 29 years
of age. A significant increase in prevalence of HB in-
fection was observed with increase in age (P = 0.0002,
chi-squared test).
The rate of anti-HBs seropositivity was 98.1% (424/
432) in children, 17.7% (22/124) in adolescents, and
28.9% (107/370) in adults (Table 2). All 432 children
were anti-HBc negative. The rate of anti-HBc seropositivity
Table 1 Number of participating children, adolescents, and adults (born after or before the launch of immunization
program) under each health service division
No. of participants tested*/total number of recruited participants (%)
Born after launch of HBB immunization program Born before launch of HBB immunization program
Division Children (6 mos. to <5 yrs. old) Adolescents (16 to 20 yrs. old) Adults (21 to 49 yrs. old) Total
Central 193/204 (94.6%) 50/50 (100%) 149/150 (99.3%) 392/404 (97.0%)
Western 168/175 (96.0%) 49/50 (98.0%) 148/150 (98.7%) 365/375 (97.6%)
Northern 71/71 (100%) 25/25 (100%) 73/75 (97.3%) 169/171 (98.85)
Total 432/450 (96.0%) 124/125 (99.2%) 370/375 (98.7%) 926/950 (97.5%)
*Refers to the number of participants with the blood samples subjected to serological tests.
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21–29, 30–39 and 40–49, respectively. The rate of anti-
HBc seropositivity was 17.4% (86/494) for adolescents and
adults, and 9.2% (86/926) overall.
The combined results for the detection of the three
serologic markers for HB infection used in this study
showed that 424 out of 432 (98.1%) children, 15 out of
124 (12.1%) adolescents and 59 out of 370 adults (15.9%)
were positive for anti-HBs but not for the other two
markers and thus can be considered immune to HBV in-
fection due to vaccination (Table 3). The total number
of adolescents and of adults positive to anti-HBS was ac-
tually 22 (17.7%) and 105 (28.4%), respectively, if those
positive to anti-HBc were included (Table 3). Eight
children (1.9%) were negative to all the tests in spite of
the fact that they received a complete series of HB
immunization (Table 3). There were 94 adolescents (75%)
and 232 adults (62.7%) who were negative to all the sero-
logical tests (Table 3).
Prevalence rates of HBsAg among adult population
showed geographic variations with significantly higher
prevalence (P = 0.0081) in the urban Central Division
(Table 4). Significantly higher prevalence of HBsAg positiv-
ity (P = 0.03, chi-squared test) was observed in female par-
ticipants in this survey (Table 4). A higher immunity level
by vaccination was seen in the Northern Division but thisTable 2 Prevalence of hepatitis markers among the participan
Age group HBsAg anti-HBs
No. positive/no.tested % 95%CI No. positive/no
Children
6 mos – <5 yrs 0/432 0.0% 0.0-1.1 424/432
Adolescent
16-20 yrs 7/124 5.6% 2.3-11.3 22/124
Adult (n = 370)
21-29 yrs 2/124 1.6% 0.2-5.7 34/124
30-39 yrs 5/123 4.1% 1.3-9.2 39/123
40-49 yrs 5/123 4.1% 1.3-9.2 34/123
Total 19/926 2.0% 1.3-3.2 553/926was not significant. Among the different ethnic groups,
Fijians had significantly the highest rate (P = 0.0041, chi-
squared test) of HB infection (Table 4).Hepatitis B immunization coverage
Immunization coverage rate in this study was defined as
the percentage of children who received at least three
doses of HB vaccine. There were 439 children whose
immunization data were available for review (Table 5).
The immunization coverage based on child health card
was very high in the three divisions (>98% per division;
total average of 99.3%). A total of 379 (86.3%) children
received the first dose (“birth dose”) of HB vaccine
within 2 days from birth. WHO`s recommendation is
that the first dose of hepatitis B vaccine be given within
24 hours of birth [9].
“On-schedule” for immunization was defined as giving
a one month leeway after due date of third HB vaccine
dose to explore timeliness of HBV immunization [10].
This definition was applied to children between 6 months
to < 2 years of age and born after the change of previous
Fiji’s HBV standard immunization schedule for 3 doses
to the present schedule for four doses of vaccine given
at birth, 6, 10 and 14 weeks [5,6,8]. The result shows that
58.5% of children were on-schedule overall (Table 5).ts grouped according to their age
anti-HBc
.tested % 95%CI No. positive/no.tested % 95%CI
98.1% 96.2-99.1 0/432 0.0% 0.0-1.1
17.7% 11.5-25.6 11/124 8.9% 4.5-15.3
27.4% 19.8-36.2 22/124 17.7% 11.5-25.6
31.7% 23.6-40.7 27/123 22.0% 15.0-30.3
27.6% 20.0-36.4 26/123 21.1% 14.3-29.4
59.7% 56.5-62.9 86/926 9.2% 7.5-11.3
Table 3 Number of children, adolescents and adults according to the combination of results for the detection of
serologic markers for HB infection and interpretation of results
Serologic markers Children







Combination HBsAg anti-HBc anti-HBs Interpretation [1,2]
1 - - - 8* 94 232 326 susceptible, never infected
2 + - - 0 4 4 8 early acute infection
3 + + - 0 3 6 9 acute or chronic infection
4 - + - 0 1 21 22 past infection or false positive
(i.e. susceptible), or “low level”
chronic infection
5 - + + 0 7 46 53 Past infection; recovered and
immune
6 + - + 0 0 0 0 —————
7 - - + 424 15 59 74 Immune due to hepatitis B vaccine
8 + + + 0 0 2 2 Acute or chronic infection
Total 432 124 370 494
*Received complete series of immunization.
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The HBV immunization program has been in place in
Fiji since the 1990s and this study is timely with a hy-
pothesis that prevalence of HBV infection should be
negligible or low among the children. All 432 children
were negative to both HBsAg and anti-HBc and this
adds some support to this hypothesis. However, a few
(8/432) were negative to anti-HBs or did not form anti-
body after completing 3 doses of HB vaccination on
schedule. The non-seroconversion of antibody against
HBV or the natural decline in the level of the antibodies
to undetectable level (<10 mIU/mL) through time is a
possible explanation [11,12]. Studies have shown that
anti-HBs concentrations declines rapidly within the firstTable 4 Prevalence of hepatitis markers among the adult resi
grouping
HBsAg anti-HBs
No. positive/no.tested % 95%CI No. positive/no.t
21-49 years 12/370 3.2% 1.8-5.8 107/370
Division
Central 10/149 6.7% 3.3-12.0 50/149
Western 1/148 0.7% 0.0-3.7 17/148
Northern 1/73 1.4% 0.0-7.4 40/73
Gender
Male 7/310 2.3% 1.0-4.8 88/310
Female 5/60 8.3% 2.8-18.4 19/60
Ethnic group
Fijian 9/137 6.6% 3.0-12.1 73/137
Indian 1/204 0.5% 0.0-2.7 20/204
Others 2/29 6.9% 0.8-22.8 14/29year and more slowly thereafter. However, despite the
possible decline to less than detectable level, there re-
main some levels of protection against HBV infection
due to immune memory [13,14].
The prevalence of HBsAg among children immunized
is less (0.0%) compared to 0.7% in 1998 (Table 6), sug-
gesting the effectiveness of the HB vaccine and effective-
ness of the childhood immunization program in the
country. A prevalence of 3.2% of HBsAg and 20.3% of
anti-HBc was found in the adult population. The exclu-
sion of a number of previous high-risk blood donors
with HBV from the survey, confirms the circulation of
the hepatitis B infection in the adult population [15]. A
higher prevalence of HB infection among the adultdents classified based on locality, gender and ethnic
anti-HBc
ested % 95%CI No. positive/no.tested % 95%CI
28.9% 24.4-33.9 75/370 20.3% 16.4-24.8
33.6% 26.0-41.7 35/149 23.5% 16.9-31.1
11.5% 6.8-17.8% 19/148 12.8% 7.9-19.3
54.8% 42.7-66.5 21/73 28.8% 18.8-40.6
28.4% 23.5-33.8 63/310 20.3% 16.1-25.3
31.7% 20.3-45.0 12/60 20.0% 10.8-32.3
53.3% 44.6-61.9 50/137 36.5% 28.4-45.1
9.8% 6.1-14.7 15/204 7.4% 4.2-11.8
48.3% 29.4-67.5 10/29 34.5% 17.9-54.3
Table 5 Coverage and timeliness of hepatitis B immunization in children from each health division
Category No. of children with the feature in each category/total no. of children (%)
Central Western Northern Total
Coverage in terms of number of dose (s) received during hepatitis B immunization (total n = 439)
Three doses or more 191/194 (98.5) 173/173 (100.0) 72/72 (100.0) 436/439 (99.3)
Only two doses 3/194 (1.5) 0/173 (0.0) 0/72 (0.0) 3/439 (0.7)
Only one dose 0/194 (0.0) 0/173 (0.0) 0/72 (0.0) 0/439 (0.0)
Timeliness of birth dose (total n = 439)
Within 2 days 170/194 (87.6) 156/173 (90.2) 53/72 (73.6) 379/439 (86.3)
Day 3 – 10 16/194 (8.2) 8/173 (4.6) 17/72 (23.6) 41/439 (9.3)
Day 10 – 30 5/194 (2.6) 5/173 (2.9) 1/72 (1.4) 11/439 (2.5)
Never immunized 3/194 (1.5) 4/173 (2.3) 1/72 (1.4) 8/439 (1.8)
Timeliness of completion of 3 doses of HBV in children < 2 years
(total n = 176)
On – schedule 46/62 (74.2) 50/79 (63.3) 7/35 (20.0) 103/176 (58.5)
Delayed 16/62 (25.8) 29/79 (36.7) 28/35 (80.0) 73/176 (41.5)
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sible explanation could be that large urban population
has the largest segment of uninformed personnel and
other risk occupational groups for sexually transmitted
diseases.
Two hundred thirty two of the adult participants
(62.7%) and 94 (75%) of adolescents had never been in-
fected with HBV and were not immune (i.e. they were
susceptible) to HBV infection (HBsAg, anti-HBs and
anti-HBc negative). Current treatment of HBV infection
is not highly effective, therefore, HB immunization is
recommended for the above unimmunized populations
[1,16]. There is a need to strengthen efforts to reach this
susceptible populations with HBV vaccination. The offer
of HBV immunization to this age group in institutions
should be strengthened. These institutions should not be
limited to health care facilities, hostels, boarding schools,
blood banks, etc. Secondly, the Ministry of Health
should actively advocate HBV vaccination in its sexual
reproductive health and adolescence health programs.
From among the 494 adolescents and adults, 86
(17.4%) had evidence of past HBV infection (anti-HBcTable 6 Comparison of test results of hepatitis B markers sur
Immunized children
1998a 2008
HBsAg positive 2/285 (0.7%) 0/432 (0.0
anti-HBs positive 217/282 (77.0%) 424/432 (
anti-HBc positive 15/281 (5.3%) 0/432 (0.0
a1998 survey results were for children (<6 years old) who were immunized with hep
bUnimmunized adults surveyed in 1998 were mothers who were born before hepat
cUnimmunized adults surveyed in 2009 were from this present study; their ages we
incorporated in the childhood immunization program.positive) for which 75 (87.2%) did not develop chronic
infection (anti-HBc positive but HBsAg negative) but a
remaining 11 (12.8%) became chronic carriers (anti-HBc
and HBsAg positive). These results are also observed in
other studies with a few identified as carriers while
others in complete recovery [12,17].
The test results showed 22 (4.5%) adolescents and adults
were anti-HBc positive but negative to the other two
markers for HBV infection. Although, a typical interpret-
ation is a history of past HBV infection, it is also possible
that it was a false positive result (i.e. susceptible) or the
participant had a “low level” chronic infection [1,2].
Although the criteria for the sample population are
different from 1998, this study suggests a possible de-
cline in the prevalence of HBsAg positives and anti-HBc
negatives among immunized children and unimmunized
adults (Table 6). The prevalence of HBsAg among unim-
munized population has decreased from 6.6% in 1998
[8], surveyed among mothers representing unimmunized
population, to 3.2% in this survey. The reasons for this
decrease are unknown, however, it may be attributed to
the increased awareness on HBV infection and itsveyed in 1998, 2008 and 2009
Unimmunized adult
1998b 2009c
%) 19/290 (6.6%) 12/370 (3.2%)
98.1%) 168/290 (57.9%) 107/370 (28.9%)
%) 195/290 (67.2%) 75/370 (20.3%)
atitis B vaccine [8].
itis B vaccine was incorporated in the child hood immunization program [8].
re from 21 to 49 years and they were born before hepatitis B vaccine was
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vaccination in the population.
HBV immunization coverage found in this study was
much higher than that reported in 2007 (Table 7) [18].
Reported coverage may be influenced by overestimated
denominators, target population, and underestimated
numerators based on inaccurate or delayed submission
of monthly reports on the number of vaccine doses ad-
ministered. However, coverage data are often verified
with regular coverage surveys.
In terms of prevention of HBV, preventing infections
acquired at birth and in early childhood is critical. The
key to reduce mother-to-child transmission is timely ad-
ministration of the first dose of the Hepatitis B vaccine
within 24 hours of birth. Efficacy of the vaccine in pre-
venting perinatal transmission declines with increasing
intervals between birth and the time of administration of
the vaccine [9].
The overall, immunization coverage for the first dose
of HB vaccine at birth in this study was very good at
98%. However, timeliness of the first dose administration
remains a challenge. About 15% of children received the
first dose of HB vaccine unacceptably late.
A trend of lower proportion for both timely administra-
tion of first HB immunization (P = 0.0009, chi-squared test)
and “on-schedule” immunization in Northern Division
were observed. Delayed immunization is not a major prob-
lem if the child completes a series of HB immunization
however, timeliness of HB birth dose should be ensured.
There are several limitations to this study. The time and
travel constraints could not accommodate the samples
from remote outer islands. This survey could not yield in-
formation on the rate of HBV infections in children who
were born to HBsAg positive mothers as participating
children were randomly selected. Despite its limitations,
this study is the first to describe the prevalence of HBV in-
fection in different age groups. The results will help public
health officials in Fiji in their plan for strengthening pro-
grammatic actions for hepatitis B control.
Conclusion
This survey suggests a successful HB immunization pro-
gram in Fiji. The program that has been in place since
1989 has led to a further reduction of HBV infectionTable 7 Comparison of the immunization coverage in
children for 2007 and for the present study in the three
health divisions
% coverage for 2007 [18] (% coverage for the
present study)
Central Western Northern Total
Birth dose 67.4 (98.5) 92.0 (97.7) 89.3 (98.6) 80.3 (98.2)
Third dosea 76.3 (98.5) 88.0 (100.0) 83.6 (100.0) 81.9 (99.3)
aThird dose of hepatitis B immunization was given as DTP-HepB-Hib.rates in the population and increase of immunity levels
among children since the introduction of the program.
Methods
Study setting, immunization records and sample
collection
A serologic survey was conducted from three out of the
four health service divisions in Fiji namely Central,
Western, and Northern Divisions. Participants from the
Eastern Division, were excluded from this survey due to
distance and time constraints. Two different survey set-
tings were followed. In the first setting, a total of 450
healthy children aged 6 months to <5 years were recruited
in the three health service divisions from September to
October 2008 (Figure 1 and Table 1). A sampling size of
450 was calculated based on the estimated population per
the target age group using the cluster survey method.
These children were likely vaccinated with HBV at birth
as part of the national HB immunization program. Zone
nurses at the three selected divisions facilitated child
listing exercise to ensure that the target numbers per div-
ision were proportionate. Blood collection for the survey
was done at the health centers. The health record card of
each child was reviewed to calculate HB immunization
coverage rates and describe any association between
immunization status and serologic tests. In the second
setting, a total of 125 healthy adolescents (16–20 years of
age) born after the launch of the national HB immunization
program and a total of 375 adults (21–49 years of age) born
before the launch were recruited in the three divisions from
May to July 2009. For determining the sampling size of
adolescent and adults, time, travel and financial constraints
were considered. Thus 100 target samples (25 adoles-
cents and 75 adults) at Northern Division (Labasa area),
and 200 target samples (50 adolescents and 150 adults)
each at Central Division (Suva) and Western Division
(Lautoka) were found practical and less expensive and
valid for the representative estimates for three different
divisions and two different age categories (Table 1).
These individuals were recruited from the blood bank
services and only the blood samples they donated for
the first time were included. Succeeding blood samples
from repeat safe donors (those safe donors who donated
blood repeatedly) and all blood samples from high risk do-
nors (e.g. recognizable person with HBV infection, sex
contacts of person with HBV infection) were excluded.
The survey on adolescents and adults provided additional
information on the extent of hepatitis B infection in the
population. Blood samples were collected after obtaining a
written consent from adult participants and parents of en-
rolled minors. Convenience sampling of the adult popula-
tion from the blood banks was done in a manner that
would ensure blood samples were proportionally repre-
sentative of the different age groups.
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The National Health Research Committee (NHRC) of
Fiji provided ethical approvals for the survey on children
on 11 September 2008 (FNRERC Reference Number:
2008–026) and for adolescents and adults on 11February
2009 (FNRERC Reference Number: 2009–002).
Serologic tests
A sample of at least 5 ml of venous blood was obtained
from each participant and sample was centrifuged on the
day of collection. The serum samples were then trans-
ported on ice to the National Public Health Laboratory of
Mataika house (Fiji Centre for Communicable Disease
Control) in Suva, Fiji. Serological tests for children sam-
ples were conducted at Mataika house, FFCDC while ado-
lescent and adults samples were tested at the Department
of Virology, Institute of Tropical Medicine at Nagasaki
University in Japan. HBsAg, anti-HBs and anti-HBc were
detected by Reverse Passive Hemagglutination (RPHA)
(Mycel II HBsAg; Institute of Immunology, Co., Ltd,
Tokyo, Japan), Passive Hemagglutination (PHA) (Mycell II
anti-HBs; Institute of Immunology Co., Ltd, Tokyo, Japan),
and PHA (Mycell anti-rHBc) methods respectively. The
samples further underwent confirmatory testing for anti-
HBC by enzyme-linked immunosorbent assay (ELISA) kit
(DRG®Anti-Hbc ELISA, DRG International, Inc. USA).
A positive result for HBsAg, for anti-HBs, and for
anti-HBc was interpreted as the participant having on-
going or chronic infection with HBV, having immunity
from HBV infection, and having past HBV infection, re-
spectively [1,16].
Analysis of data
All the epidemiological and laboratory data were ana-
lyzed blindly in Epi info Version 3.3.2. A chi-square test
was applied with a p < 0.05 level of significance.
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